Metabolon Awarded Analytical Methods Patent
RESEARCH TRIANGLE PARK, N.C. (March 27, 2012) — Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology, announces the grant of US Patent 8,131,473 "Data Analysis Methods for Locating Entities of Interest within Large Multivariable Datasets." The patent was issued on March 6, 2012 and is the sixth technology patent and nineteenth patent overall awarded to Metabolon. The invention describes analysis methods and computational tools developed by Metabolon to quickly and accurately locate biochemicals, genes and proteins of interest in large multivariate data.
The use of genomics, proteomics and metabolomics to answer a variety of biological questions has increased dramatically over the last few years. These ‘omics sciences generate massive amounts of data, and sifting through that data to identify biologically significant changes is a major rate-limiting step. The patented method enables the researcher to process, analyze, and interpret data more efficiently. Through the implementation of these techniques, the relevant changes in transcripts, proteins and biochemicals in an experimental sample can be quickly and accurately identified. This enables the interpretation of the results, and facilitates the understanding of biological mechanisms and modes of action.
Metabolon, Inc. has advanced the field of metabolomics by pioneering and patenting the industry’s leading biochemical biomarker discovery and profiling platform. It has developed the technology to quickly identify and measure all of the biochemicals in a biological sample through its proprietary global processing method. Through the generation and interpretation of data, this method provides a precise understanding of disease etiology and drug action, and advances personalized medicine beyond what genomics and other approaches can promise. Metabolon’s expertise is being embraced by a wide range of pharmaceutical, biotechnology, food and agricultural companies. Metabolytics, its biomarker discovery and analysis business, has completed over 350 client studies and processed over 50,000 samples for customers in 2011 alone. Building on its expertise in biochemistry understanding, Metabolon is also developing proprietary diagnostic tests to determine and track disease progression. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske at firstname.lastname@example.org or 919-595-2200.